Zosano Pharma’s Pipeline
The following table summarizes the status of the Company’s development programs:
Zosano Pharma intends to partner selectively to expand the utilization of the proprietary transdermal delivery platform. The Company will continue to selectively collaborate with third parties with respect to delivery of their proprietary drugs, as well as collaborate with third parties to pursue clinical and commercial development of its own products in geographies outside the United States where it may be more cost effective to do so.
* Qtrypta (zolmitriptan intracutaneous microneedle system) is the proposed tradename that has been conditionally approved by FDA. Zosano will seek approval of the tradename when an NDA is filed for the product.